Navigation Links
Celiac Disease Sufferers See an End to their Misery

Celiac disease sufferers often endure a life of dietary restrictions, ensuring that no gluten, a product found in many commonly eaten foods//, ever passes their lips.

But this may soon come to an end. Researchers in the Netherlands have found that an enzyme originally developed for commercial food processing -- AN-PEP -- may be able to break down gluten in the stomach before it reaches the small intestine. This information could be vital because the small intestine is where celiac disease originates.

According to the study's lead author, Frits Konig, professor of immunology at Leiden University Medical Center "There is a realistic chance that this enzyme can be used to develop an alternative treatment for celiac disease. It is very difficult to predict if such an enzyme-based treatment would actually be preferred over a gluten-free diet, but at the very least, it would provide patients with the option to occasionally follow a normal diet -- for example, when going out or during other social occasions, times when a gluten-free diet is certainly bothersome.

The results of the research have been published in the online journal American Journal of Physiology - Gastrointestinal and Liver Physiology. .

According to Konig about 1 percent of people in the United States and Europe are affected by celiac disease which is an autoimmune disease. It occurs when the body mistakes gluten molecules as foreign invaders to be destroyed. As a result parts of the small intestine are also destroyed along with the gluten moleculesduring the immune system response. This leads to a difficulty for the small intestine to properly absorb nutrients from food causing anemia and vitamin deficiencies. .

Therefore the only solution for avoiding the flare up of this disease would be to avoid gluten completely. However this is not an easy task. As Konig pointed out, "Gluten is a common protein found in wheat and related cereals like barley and rye. This
'"/>




Page: 1 2

Related medicine news :

1. Celiac Disease in Type 1 Diabetes
2. Research on Celiac Disease in children
3. Understanding The Link Between Celiac Disease And Osteoporosis
4. Scientists Discover Non-dietary Therapy For Celiac Diseases
5. Center for Celiac Disease Opens
6. Potential Link Between Celiac Disease and Cognitive Decline
7. Prevalence of Celiac disease in children with type 1 diabetes
8. From the frying pan into the fire: Celiac disease and diabetes
9. Gluten Free Bread: Boon for Celiac Disease
10. Research Finds No Link Found Between Autism and Celiac Disease
11. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
Post Your Comments:
Breaking Medicine News(10 mins):Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 2Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 3Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 4Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 5Health News:The Breema Center Presents a Yearlong Campaign to Transform Stress into Harmony in 2010 and Beyond 2Health News:Anesiva Stockholders Approved Merger With Arcion Therapeutics but Merger Remains Contingent on Other Closing Conditions 2Health News:Anesiva Stockholders Approved Merger With Arcion Therapeutics but Merger Remains Contingent on Other Closing Conditions 3Health News:Frost & Sullivan to Hold Web Conference on Integrated Hospital Pharmacy Information Systems - How to Maneuver towards Growth Potential 2Health News:InfoZoom Launches V6.4 of its Industry Leading In-Memory Data Analysis Software 2Health News:InfoZoom Launches V6.4 of its Industry Leading In-Memory Data Analysis Software 3
Breaking Medicine Technology:Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy 2Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 2Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 4Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 5Frost 26amp 3B Sullivan Recognizes Fovia for its HDVR 28R 29 Platform A Disruptive Technology Breakthrough 6205 1Frost 26amp 3B Sullivan Recognizes Fovia for its HDVR 28R 29 Platform A Disruptive Technology Breakthrough 6205 2Frost 26amp 3B Sullivan Recognizes Fovia for its HDVR 28R 29 Platform A Disruptive Technology Breakthrough 6205 3Frost 26amp 3B Sullivan Recognizes Fovia for its HDVR 28R 29 Platform A Disruptive Technology Breakthrough 6205 4Colorado MRI Clinic Blends Ultra Patient Care with Significant Cost Savings 6201 1Colorado MRI Clinic Blends Ultra Patient Care with Significant Cost Savings 6201 2Colorado MRI Clinic Blends Ultra Patient Care with Significant Cost Savings 6201 3Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 1Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 2Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 3Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 4Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 5Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 6